Biovie

FY2026 EarningsFY26 full-year results were mixed relative to consensus: revenue met the zero-revenue expectation ($0M), while EBIT loss of -$22.7M was wider than the -$22.5M mean estimate. Net loss (GAAP) was slightly better at -$22.1M vs. -$22.2M expected, primarily due to higher-than-anticipated interest income. The most significant development was the successful primary endpoint achievement in the Phase 2b SUNRISE-PD trial for Parkinson's disease, though a 'going concern' warning persists due to a $9.0M cash balance against a $22.1M annual burn rate.